During the last few years, considerable focus has been given to the management of anemia and coagulopathies. This article provides current concepts of red blood cell (RBC) and plasma coagulation factor replacements.
Methods
The literature was reviewed for clinical studies relevant to RBC transfusion indications and outcomes as well as for the uses of coagulation factor replacement products for coagulopathies most likely encountered in patients with cancer.
Results
Most patients without complications can be treated with a hemoglobin level of 7 g/dL as an indication for RBC transfusion. However, the effects of disease among patients with cancer may cause fatigue, so transfusions at higher hemoglobin levels may be clinically helpful. Leukoreduced RBCs are recommended as standard therapy for all patients with cancer, most of whom do not develop coagulopathy. Transfusions to correct mild abnormalities are not indicated in this patient population. Data are inconclusive regarding the value of coagulation factor replacement for invasive procedures when the international normalized ratio is below 2.
Conclusions
Indications for RBC transfusion have become more conservative as data and experience have shown that patients can be safely and effectively maintained at lower hemoglobin levels. Coagulation factor replacement is unnecessary for most modest coagulopathies.
References
1.
ShorttJ., PolizzottoM.N., WatersN.. Assessment of the urgency and deferability of transfusion to inform emergency blood planning and triage: the Bloodhound prospective audit of red blood cell use.Transfusion.2009; 49(11): 2296–2303.
2.
EstrinJ.T., SchocketL., KregenowR.. A retrospective review of blood transfusions in cancer patients with anemia.Oncologist.1999; 4(4): 318–324.
3.
DicatoM., PlawnyL., DiederichM.. Anemia in cancer.Ann Oncol.2010; 21(Suppl 7): vii167–172.
4.
TasF., EralpY., BasaranM.. Anemia in oncology practice: relation to diseases and their therapies.Am J Clin Oncol.2002; 25(4): 371–379.
5.
National Institutes of Health (NIH).NIH Consensus Conference on Use of Red Cells.3rd ed.Bethesda, MD: NIH; 1988.
6.
TasF., EralpY., BasaranM.. Anaemia in oncology practice: relation to diseases and their therapies.Am J Clin Oncol.2004; (suppl 1): 11–26.
7.
GroopmanJ.E., ItriL.M.. Chemotherapy-induced anemia in adults: incidence and treatment [Erratum in J Natl Cancer Inst. 2000;92(6): 497].J Natl Cancer Inst.1999; 91(19): 1616–1634.
8.
StasiR., AbrianiL., BeccagliaP.. Cancer-related fatigue: evolving concepts in evaluation and treatment.Cancer.2003; 98(9): 1786–1801.
9.
LittlewoodT.J., BajettaE., NortierJ.W.; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.J Clin Oncol.2001; 19(11): 2865–2874.
10.
CabralesP., TsaiA.G., FrangosJ.A.. Oxygen delivery and consumption in the microcirculation after extreme hemodilution with perfluorocarbons.Am J Physiol Heart Circ Physiol.2004; 287(1) H320–H330.
11.
WilkersonD.K., RosenA.L., SehgalL.R.. Limits of cardiac compensation in anemic baboons.Surgery.1988; 103(6): 665–670.
12.
WeiskopfR.B., VieleM.K., FeinerJ.. Human cardiovascular and metabolic response to acute, severe isovolemic anemia.JAMA.1998; 279: 217–221.
13.
ToyP., FeinerJ., VieleM.K.. Fatigue during acute isovolemic anemia in healthy, resting humans.Transfusion.2000; 40(4): 457–460.
14.
GrimshawK., SahlerJ., SpinelliS.L.. New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells.Transfusion.2011; 51(4): 874–880.
15.
BlumbergN.. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt.Transfusion.2005; 45 (2 suppl): 33S–40S.
16.
TinmouthA1, FergussonD., YeeI.C.; ABLE Investigators; Canadian Critical Care Trials Group. Clinical consequences of red cell storage in the critically ill.Transfusion.2006; 46(11): 2014–2027.
17.
HébertP.C., WellsG., BlajchmanM.A.; Transfusion Requirements in Critical Care Investigators; Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care [Erratum appears in N Engl J Med. 1999;340(13): 1056].N Engl J Med.1999; 340(6): 409–417.
18.
VincentJ.L., BaronJ.F., ReinhartK.; Anemia and Blood Transfusion in Critical Care Investigators. Anemia and blood transfusion in critically ill patients.JAMA.2002; 288(12): 1499–11507.
19.
CorwinH.L., GettingerA., PearlR.G.. The CRIT Study: Anemia and blood transfusion in the critically ill–current clinical practice in the United States.Crit Care Med.2004; 32(1): 39–52.
20.
CarsonJ.L., TerrinM.L., NoveckH.. Liberal or restrictive transfusion in high-risk patients after hip surgery.N Engl J Med.2011; 365(26): 2453–2462.
21.
HébertP.C.; Transfusion Requirements in Critical Care. The TRICC trial: a focus on the sub-group analysis.Vox Sang.2002; (83 suppl): 387–396.
22.
LacroixJ., HébertP.C., HutchisonJ.S.; TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators Network. Transfusion strategies for patients in pediatric intensive care units.N Engl J Med.2007; 356(16): 1609–1619.
23.
NelsonA.H., FleisherL.A., RosenbaumS.H.. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit.Crit Care Med.1993; 21(6): 860–866.
24.
WhitmanC.B., ShreayS., GitlinM.. Clinical factors and the decision to transfuse chronic dialysis patients.Clin J Am Soc Nephrol.2013; 8(11): 1942–1951.
25.
BergerM.D., GerberB., ArnK.. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation.Haematologica.2012; 97(1): 116–122.
26.
CarsonJ.L., GrossmanB.J., KleinmanS.. Red blood cell transfusion: a clinical practice guideline from the AABB.Ann Intern Med.2012; 157(1): 49–58.
27.
McCulloughJ.J.. Complications in transfusion. In: McCulloughJ.J.. Transfusion Medicine.3rd ed.Chichester, West Sussex, UK: Wiley-Blackwell; 2011.
28.
LelubreC., PiagnerelliM., VincentJ.L.. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality?Transfusion.2009; 49(7): 1384–1394.
29.
OpelzG., SengarD.P., MickeyM.R.. Effect of blood transfusions on subsequent kidney transplants.Transplant Proc.1973; 5(1): 253–259.
30.
BlumbergN., HealJ.M.. Evidence for plasma-mediated immunomodulation–transfusions of plasma-rich blood components are associated with a greater risk of acquired immunodeficiency syndrome than transfusions of red blood cells alone.Transplant Proc.1988; 20(6): 1138–1142.
31.
VamvakasE.C., CarvenJ.H.. Allogeneic blood transfusion, hospital charges, and length of hospitalization: a study of 487 consecutive patients undergoing colorectal cancer resection.Arch Pathol Lab Med.1998; 122(2): 145–151.
32.
BlajchmanM.A.. Immunomodulatory effects of allogenic blood transfusions: Clinical manifestations and mechanisms.Vox Sang.1988; 74(Suppl 2): 315.
33.
KorD.J., Van BuskirkC.M., GajicO.. Red blood cell storage lesion.Bosn J Basic Med Sci.2009; (9 suppl 1): 21–27.
34.
LutenM., Roerdinkholder-StoelwinderB., SchaapN.P.. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods.Transfusion.2008; 48(7): 1478–1485.
35.
JabbourE., KantarjianH.M., KollerC.. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.Cancer.2008; 112(5): 1089–1095.
36.
American Association of Blood Banks (AABB).Standards for Blood Banks and Transfusion Services.27th ed.Bethesda, MD: AABB; 2014.
37.
RatkoT.A., CummingsJ.P., ObermanH.A.; University Health System Consortium. Evidence-based recommendations for the use of WBC-reduced cellular blood components.Transfusion.2001; 41(10): 1310–1399.
38.
SharmaR.R., MarwahaN.. Leukoreduced blood components: advantages and strategies for its implementation in developing countries.Asian J Transfus Sci.2010; 4(1): 3–8.
39.
WenzB.. Microaggregate blood filtration and the febrile transfusion reaction. A comparative study.Transfusion.1983; 23(2): 95–98.
40.
BlumbergN., HealJ.M., GettingsK.F.. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions.Transfusion.2010; 50(12): 2738–2744.
41.
SillimanC.C., PatersonA.J., DickeyW.O.. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study.Transfusion.1997; 37(7): 719–726.
42.
Trial to Reduce Alloimmunization to Platelets Study Group.Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.N Engl J Med.1997; 337(26): 1861–1869.
43.
BowdenR.A., SlichterS.J., SayersM.. A comparison of filtered leukocyte reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.Blood.1995; 86(9): 3598–3603.
44.
MillerW.J., McCulloughJ., BalfourH.H.. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.Bone Marrow Transplant.1991; 7(3): 227–234.
45.
GilbertG.L., HudsonI.L., HayesJ.J.. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes.Lancet.1989; 1(8649): 1228–1231.
46.
HillyerC.D., EmmensR.K., Zago-NovarettiM.. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units.Transfusion.1994; 34(10): 929–934.
47.
McCulloughJ.J.. Clinical uses of blood components. In: McCulloughJ.J.. Transfusion Medicine.3rd ed.Chichester, West Sussex, UK: Wiley-Blackwell; 2011.
48.
ThalerM., ShamissA., OrgadS.. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery.N Engl J Med.1989; 321(1): 25–28.
O'ShaughnessyD.F., AtterburyC., Bolton MaggsP.; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.Br J Haematol.2004; 126(1): 11–28.
51.
Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists.Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets.JAMA.1994; 271(10): 777–781.
52.
CohnC.S., StubbsJ., SchwartzJ.. A comparison of adverse reaction rates for PAS C versus plasma platelet units.Transfusion.2014; 54(8): 1927–1934.
53.
GoodnoughL.T., LevyJ.H., MurphyM.F.. Concepts of blood transfusion in adults.Lancet.2013; 381(9880): 1845–1854.
54.
CarlsonK.S., DeSanchoM.T.. Hematological issues in critically ill patients with cancer.Crit Care Clin.2010; 26(1): 107–132.
55.
StanworthS.. The evidence based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy.Hematology Am Soc Hematol Educ Program.2007; 179–186.
56.
McCulloughJ.. Pathogen inactivation: a new paradigm for blood safety.Transfusion.2007; 47(12): 2180–2184.
57.
Jilma-StohlawetzP., KurstenF.W., HorvathM.. Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers.Transfusion.2013; 53(9): 1906–1917.
58.
AlaviJ.B., RoatR.K., DjerassiI.. A randomized clinical trial of granulocyte transfusions for infection of acute leukemia.N Engl J Med.1977; 296(13): 706–711.
59.
GrawR.H.Jr, HerzigG., PerryS.. Normal granulocyte transfusion therapy. Treatment of septicemia due to gram-negative bacteria.N Engl J Med.1972; 287(8): 367–371.
60.
HerzigG.P., GrawR.G.Jr. Granulocyte transfusions for bacterial infections. In: BrownE.B., ed. Progress in Hematology.Vol 9. New York: Grune & Stratton;1975: 207.
StraussR.G.. Therapeutic neutrophil transfusions: are controlled studies no longer appropriate?Am J Med.1978; 65(6): 1001–1006.
63.
LilesW.C., JuangJ.E., LlewellynC.. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers.Transfusion.1997; 37(2): 182–187.
64.
DaleD.C., LilesW.C., LlewellynC.. Neutrophil transfusions: kinetics and functions of neutrophils mobilized with granulocyte colony-stimulating factor (G-CSF) and dexamethasone.Transfusion.1998; 38(8): 713–721.
65.
RutellaS., PierelliL., PiccirilloN.. Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors.Cytotherapy.2003; 5(1): 19–30.
66.
PriceT.H., BowdenR.A., BoeckhM.. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation.Blood.2000; 95(11): 3302–3309.
67.
NicholsW.G., StraussR., AmbrusoD.. G-CSF stimulated granulocyte transfusions from unrelated community donors for severe infections during neutropenia: a phase II multi-center trial of feasibility and efficacy.Blood.2003; 102(11): 978a.
68.
PriceT.H., McCulloughJ., NessP.. A randomized controlled trial on the efficacy of high-dose granulocyte transfusion therapy in neutropenic patients with infection. Paper presented at: 56th ASH Annual Meeting and Exposition; San Francisco, CA; December 6-9, 2014. https://ash.confex.com/ash/2014/webprogram/Paper68775.html. Accessed November 13, 2014.
69.
McCulloughJ., WeiblenB.J., FineD.. Effects of storage of granulocytes on their fate in vivo.Transfusion.1983; 23(1): 20–24.
70.
GlasserL.. Effect of storage on normal neutrophils collected by discontinuous-flow centrifugation leukapheresis.Blood.1977; 50(6): 1145–1150.
71.
McCulloughJ.. Liquid preservation of granulocytes.Transfusion.1989; 20(2): 129–137.
72.
WalterR.B., LeeS.J., GardnerK.M.. Outpatient management following induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study.Haematologica.2011; 96(6): 914–917.
73.
GirmeniaC., AlimenaG., LatagliataR.. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit.Haematologica.1999; 84(9): 814–819.
74.
SchrijversD.. Management of anemia in cancer patients: transfusions.Oncologist.2011; 16(Suppl 3): 12–18.
75.
CrémieuxP.Y., BarrettB., AndersonK.. Cost of outpatient blood transfusions in cancer patients.J Clin Oncol.2000; 18(14): 2755–2761.
76.
SlichterJ., KaufmanR., AssmannS.F.. Dose of prophylactic platelet transfusions and prevention of hemorrhage.N Engl J Med.2010; 362(17): 600–613.
77.
GoodnoughL.T., KuterD.J., McCulloughJ.. Prophylactic platelet transfusions from healthy normal apheresis platelet donors undergoing treatment with thrombopoietin.Blood.2001; 98(5): 1346–1351.
